Orexigen Therapeutics Revenue Quarterly YoY Growth:
0.00% for Dec. 31, 2012Orexigen Therapeutics Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 0.00% |
| Sept. 30, 2012 | 0.00% |
| June 30, 2012 | 0.00% |
| March 31, 2012 | -53.12% |
| Dec. 31, 2011 | -2.50% |
| Sept. 30, 2011 | 178.2% |
| June 30, 2011 | 3795% |
| March 31, 2011 | 8209% |
| Dec. 31, 2010 | 3895% |
| Sept. 30, 2010 | 1300% |
| June 30, 2010 | 0.00% |
| March 31, 2010 | 0.00% |
| Dec. 31, 2009 | 0.00% |
| Sept. 30, 2009 | 0.00% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
OREX Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Vivus | |
| Arena Pharmaceuticals | 8.41% |
| Pernix Therapeutics | -14.98% |
OREX Revenue Quarterly YoY Growth Rankings
| Overall |
59th percentile 3068 of 7590 |
| Sector |
50th percentile 323 of 651 in Healthcare |
| Industry |
52nd percentile 31 of 65 in Drug Manufacturers - Specialty & Generic |
OREX Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -53.12% | Mar 2012 |
| Maximum | 8209% | Mar 2011 |
| Average | 911.7% |
